Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProLectin-A
- Development stage
- Preclinical
- Lead developer
- BioXyTran
- Administration
- Intravenous
01
Overview
ProLectin-A is an investigational intravenous galectin antagonist being developed by BioXyTran for the treatment of acute respiratory distress syndrome (ARDS) secondary to COVID-19. It is a carbohydrate-based therapeutic designed to target galectins, specifically by blocking the galectin fold on the N-terminal domain (NTD) of the SARS-CoV-2 spike protein. This mechanism is intended to inhibit viral adhesion and entry while simultaneously modulating the immune response to reduce macrophage trafficking and the subsequent cytokine storm, thereby restoring immune homeostasis in severe cases.
Beyond the preview
Go deeper on ProLectin-A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProLectin-A.